DXNVX Signs Contract to Introduce Anti-Cancer Vaccine from UK Oxford BackMedics

DxVx announced on the 12th that it has signed a contract to introduce the anticancer vaccine ‘OVM-200’ with Oxford Vacmedix (OVM) in the UK.

The two companies had previously agreed on the key terms related to the license agreement earlier this year. With the signing of this license agreement, clinical trials outside the UK are expected to proceed in earnest. DxVx has secured the rights for research, development, and commercialization of OVM-200 in Korea, China (including Hong Kong, Macau, and Taiwan), and India.

OVM-200 is a therapeutic vaccine that enters the body and eliminates cancer cells. Even as new cancer cells develop over time, immune cells remember and eradicate them. Animal tests have also observed cancer prevention effects, indicating a high potential for development as a preventive cancer vaccine.

In particular, the ROP (Recombinant Overlapping Peptide) technology applied to the OVM-200 anticancer vaccine enhances immunity and increases vaccine efficacy. Additionally, targeting Survivin, which is expressed in most cancer types, is considered a differentiating factor.

Currently, OVM-200 has successfully completed Phase 1a clinical trials in the UK and has administered the vaccine to five patients in Phase 1b trials. Interim results of the UK Phase 1b trial are expected to be announced in the first half of next year.

DxVx plans to conduct domestic and international clinical trials of OVM-200, and with the completion of this introduction contract, the pace of clinical trials and commercialization is expected to accelerate. OVM-200 is a first-in-class, best-in-class anticancer drug targeting Survivin. Given Survivin’s expression in various cancer types, promising results are anticipated not only in solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, and prostate cancer but also in hematologic cancers.

Kyu-Chan Kwon, CEO of DxVx, stated, "We are pleased to have completed the contract for the introduction of this innovative anticancer vaccine. Preparations for clinical progress have already begun, and discussions to secure additional rights in the Japanese region will also proceed." He added, "We aim to distribute effective drugs as soon as possible to patients suffering from cancer in the Asian region. We plan to launch the product as quickly as possible through expedited development programs such as Accelerated Approval."

Meanwhile, OVM is a spin-off company from the University of Oxford in the UK, with DxVx holding approximately 41% of the shares, making it the largest shareholder. Recently, DxVx has increased its stake to about 43%, maintaining its position as the largest shareholder.

This content was produced with the assistance of AI translation services.